Biologics, like monoclonal antibodies and viral vectors, make up rapidly growing classes of drugs. They are also critical research tools and essential for the development of many new diagnostics.
While chromatography has been a mainstay for small molecules, large and bulky biologics require a new approach to downstream manufacturing. Isolere Bio was founded with the vision of simplifying and streamlining the purification of biologics to improve global access to these important therapeutics.
We are currently focused on developing this technology for the manufacturing of Fc fusion proteins and adeno-associated virus (AAV), as well as enveloped viruses, nucleic acids, and enzymes. We are working to develop a low-cost, high throughput, and scalable purification platform and we are actively seeking validation and scale-up partners who share our vision for the next generation of bioprocessing.
Our product is made entirely recombinantly in E. coli and has no synthetic scaffold. This eliminates the cost of the solid support and chemical conjugation steps.
Our process scales linearly, providing a seamless transition from the bench to the clinic and into commercialization.
EASE OF USE
Our technology requires a simple tangential flow filtration (TFF) setup rather than complex chromatography equipment. It is compatible with validated, off-the-shelf filters with large pore sizes that enable high volumetric throughput.
From high throughput 96-well plates, to all-in-one kits, to bulk reagent, our technology can be tailored to suit your needs. A residual ELISA will be commercially available prior to product launch and the reagent can be provided as either research- or GMP-grade.
Complete concentration and purification with TFF in 8 hours or less. High flux will eliminate the capture step bottleneck and permeate control enables seamless development of a continuous downstream processes.
Our reagent binds and elutes the target in solution, eliminating the mass transfer constraints of traditional packed bed chromatography
Innovative, chromatography-free solutions for the efficient and scalable purification of biologics, including viral vectors, antibodies/Fc fusions, and nucleic acids.
Isolere enters into an agreement with Aldevron to develop a scalable manufacturing process for IsoTag reagents. Read more here.
Isolere welcomes Nikki Votaw back: from intern to full-time scientist. Congratulations on your successful thesis defense Dr. Votaw!
Isolere receive a Phase I SBIR award from NIH to support application of the IsoTag technology to mRNA manufacturing.
May 5, 2021
Isolere announces the closing of a $7M Series Seed financing round and is honored to join the Northpond Ventures portfolio. Read more here.
THE ISOTAG TECHNOLOGY
This process is highly platform-able! Contact us to discuss custom reagent development to your therapeutic of interest. By replacing the antibody-binding domain with a different capture domain at the gene level, this versatile technology can be applied to other biotherapeutics.
FOUNDER & CHAIRMAN OF THE BOARD
Ashutosh Chilkoti, PhD
FOUNDER & CHIEF SCIENTIFIC ADVISOR
Kelli Luginbuhl, PhD
FOUNDER & CHIEF EXECUTIVE OFFICER
Adam Wieschhaus, PhD, CFA
BOARD OF DIRECTORS
Michael Dzuricky, PhD
CHIEF SCIENTIFIC OFFICER
Rhonda Stanley, CPA
CHIEF FINANCIAL OFFICER
Yi Wang, PhD, MBA
VP Business Development
LAB & OFFICE MANAGER
Nikki Votaw, PhD
We're hiring - join the Isolere family!
We are looking to fill several key positions:
Process Develop Research Scientist/Engineer - Take on a critical and challenging role in helping us to develop robust, scalable, and platform process solutions for diverse biologics applications. Role involves travel to collaborators' sites to help set up and ensure smooth demo runs, technology transfer, and scale up. Opportunities for management and leadership. (posting)
Product Development Manager - Take on a key role laying a pathway to market for Isolere's products. Design robust internal systems from the ground up for QC/QA that ensure successful product adoption. Manager sourcing and vendor relationships. Work closely with VP of Business Development to lay a framework for commercialization with a constant eye for product market fit and new market needs. (posting coming soon)